Medication info
Uniloba Tablet 10mg (Rosuvastatin Calcium)

Uniloba Tablet 10mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Kujoo Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
For domestic use - 30 tablets/bottle, for export - 30 tablets/box [(10 tablets/PTP x 3)], for export - 100 tablets/box [(10 tablets/PTP x 10)]
Approval status
Active

MFDS item code 201602318 · Approved 2016.04.26 · Insurance code 669804810

Summary

Main use
Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to achieve control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg per day. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.
Children's dosage
Age 10 years to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Kujoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunct when diet and exercise alone cannot control primary hypercholesterolemia and mixed dyslipidemia patients. It is especially used in conjunction with other treatments for patients with homozygous familial hypercholesterolemia, lowering total cholesterol and LDL cholesterol levels, thereby delaying the progression of atherosclerosis. It is also used as an adjunct in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia when certain criteria are met. Additionally, it is used adjunctively in the treatment of primary dysbetalipoproteinemia. This drug is effective in reducing the risk of stroke, myocardial infarction, and vascular reintervention in middle-aged patients with elevated high-sensitivity C-reactive protein and cardiovascular risk factors. Overall, this medication is used to improve blood cholesterol levels and reduce cardiovascular risks.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to achieve control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg per day. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.

Children's dosage

Age 10 years to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, patients who are allergic to any component of this drug, those with severe liver dysfunction, patients with muscle disorders, and those who are taking specific medications should avoid treatment. Additionally, women who are pregnant or breastfeeding, as well as women of childbearing potential, must consider pregnancy planning and fetal risks, and should use appropriate contraceptive methods. This medication can affect the liver and muscles, so patients with a history of liver disease, excessive alcohol consumption, and risk factors for myopathy must consult with a physician before use and be monitored carefully. During treatment, if symptoms such as muscle pain, weakness, or fever occur, inform medical personnel immediately, and if necessary, a blood test should be conducted to check for muscle damage. This drug may increase blood sugar levels in some patients; individuals at risk for diabetes should have regular blood glucose checks. Furthermore, this drug can interact with several other medications, so it is essential to inform healthcare providers about any concurrent medications, especially caution is advised when combined with specific antiviral agents, immunosuppressants, antibiotics, and fibrates. Side effects reported in clinical trials and post-marketing studies include headaches, dizziness, dyspepsia, skin rash, muscle pain, and rarely severe side effects such as liver damage or muscle rupture may occur. In case of overdose, as there is no specific antidote, immediate medical attention should be sought for treatment based on symptoms, and monitoring of liver function and muscle enzyme levels should be conducted. Finally, while this medication is unlikely to affect driving or operating machinery, caution is advised as dizziness may occur.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, increased CK, increased AST, joint pain, fatigue, numbness, sensory abnormalities, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect from air and moisture. It is best to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

For domestic use - 30 tablets/bottle, for export - 30 tablets/box [(10 tablets/PTP x 3)], for export - 100 tablets/box [(10 tablets/PTP x 10)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.